Propensity score Cox regression of influences on outcome
Parameter . | Cox regression . | Propensity score Cox regression . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
P value . | HR . | LL . | UL . | P value . | HR . | LL . | UL . | |||
OS | Conditioning | FLU/THIO/TREO | .329 | 0.8 | 0.4 | 1.3 | .543 | 0.8 | 0.4 | 1.5 |
Remission status (vs CR1) | >CR1 | .002 | 2.6 | 1.4 | 4.8 | .004 | 2.9 | 1.4 | 6.0 | |
Source (vs BM) | PB | .934 | 1.0 | 0.5 | 2.0 | .359 | 0.7 | 0.3 | 1.6 | |
Other | .218 | 2.2 | 0.6 | 7.6 | .213 | 2.4 | 0.6 | 9.3 | ||
Age (vs 4-10) | 10-14 | .676 | 1.2 | 0.6 | 2.3 | .314 | 1.5 | 0.7 | 3.5 | |
>14 | .052 | 1.9 | 1.0 | 3.5 | .052 | 2.1 | 1.0 | 4.3 | ||
Donor (vs MD) | MSD | .860 | 1.1 | 0.6 | 2.0 | .405 | 1.4 | 0.6 | 3.2 | |
MRD+ (vs MRD−) | MRD+ | .083 | 1.7 | 0.9 | 3.0 | .138 | 1.6 | 0.9 | 3.1 | |
Immune phenotype (vs BCP) | T-ALL | .096 | 1.8 | 0.9 | 3.7 | .175 | 1.8 | 0.8 | 4.0 | |
Other | .572 | 1.8 | 0.2 | 13.8 | .758 | 0.7 | 0.1 | 5.8 | ||
Country (vs NOR) | Randomizing country | .083 | 0.6 | 0.3 | 1.1 | .231 | 0.6 | 0.3 | 1.4 | |
EFS | Conditioning | FLU/THIO/TREO | .915 | 1.0 | 0.7 | 1.6 | .624 | 1.1 | 0.7 | 1.9 |
Remission status (vs CR1) | >CR1 | <.001 | 2.7 | 1.7 | 4.4 | <.001 | 2.8 | 1.6 | 5.1 | |
Source (vs BM) | PB | .776 | 1.1 | 0.6 | 1.9 | .572 | 0.8 | 0.4 | 1.6 | |
Other | .597 | 1.4 | 0.4 | 4.7 | .534 | 1.5 | 0.4 | 5.7 | ||
Age (vs 4-10) | 10-14 | .977 | 1.0 | 0.6 | 1.7 | .397 | 1.3 | 0.7 | 2.6 | |
>14 | .454 | 1.2 | 0.7 | 2.1 | .347 | 1.3 | 0.7 | 2.4 | ||
Donor (vs MD) | MSD | .654 | 1.1 | 0.7 | 1.9 | .309 | 1.4 | 0.7 | 2.8 | |
MRD+ (vs MRD−) | MRD+ | .048 | 1.6 | 1.0 | 2.6 | .084 | 1.6 | 0.9 | 2.7 | |
Immune phenotype (vs BCP) | T-ALL | .890 | 1.0 | 0.6 | 2.0 | .874 | 1.1 | 0.5 | 2.2 | |
Other | .550 | 1.6 | 0.4 | 6.6 | .570 | 0.6 | 0.1 | 2.9 | ||
Country (vs NOR) | Randomizing country | .411 | 0.8 | 0.5 | 1.4 | .883 | 0.9 | 0.5 | 1.9 | |
CIR | Conditioning | FLU/THIO/TREO | .732 | 0.9 | 0.6 | 1.5 | .982 | 1.0 | 0.5 | 1.8 |
Remission status (vs CR1) | >CR1 | .002 | 2.4 | 1.4 | 4.3 | .002 | 2.8 | 1.4 | 5.4 | |
Source (vs BM) | PB | .401 | 1.3 | 0.7 | 2.4 | .999 | 1.0 | 0.5 | 2.0 | |
Other | .881 | 0.9 | 0.2 | 3.9 | .666 | 0.7 | 0.1 | 4.5 | ||
Age (vs 4-10) | 10-14 | .799 | 0.9 | 0.5 | 1.7 | .558 | 1.3 | 0.6 | 2.8 | |
>14 | .825 | 0.9 | 0.5 | 1.7 | .797 | 1.1 | 0.5 | 2.2 | ||
Donor (vs MD) | MSD | .895 | 1.0 | 0.5 | 1.7 | .555 | 1.3 | 0.6 | 2.9 | |
MRD+ (vs MRD−) | MRD+ | .014 | 1.9 | 1.1 | 3.1 | .013 | 2.1 | 1.2 | 3.7 | |
Immune phenotype (vs BCP) | T-ALL | .779 | 0.9 | 0.4 | 2.0 | .859 | 1.1 | 0.4 | 2.7 | |
Other | .952 | 0.9 | 0.1 | 8.2 | .363 | 0.4 | 0.0 | 3.2 | ||
Country (vs NOR) | Randomizing country | .778 | 1.1 | 0.6 | 2.1 | .564 | 1.3 | 0.6 | 3.0 | |
cGVHD | Conditioning | FLU/THIO/TREO | .526 | 0.8 | 0.4 | 1.7 | .847 | 0.9 | 0.4 | 2.1 |
Remission status (vs CR1) | >CR1 | .395 | 1.4 | 0.7 | 2.8 | .228 | 1.7 | 0.7 | 3.9 | |
Source (vs BM) | PB | .683 | 1.2 | 0.5 | 2.9 | .937 | 1.0 | 0.4 | 3.0 | |
Other | .254 | 2.9 | 0.5 | 17.8 | .356 | 2.6 | 0.3 | 20.5 | ||
Age (vs 4-10) | 10-14 | .197 | 1.8 | 0.7 | 4.4 | .263 | 1.9 | 0.6 | 6.2 | |
>14 | .170 | 1.8 | 0.8 | 4.0 | .306 | 1.7 | 0.6 | 4.7 | ||
Donor (vs MD) | MSD | .706 | 0.9 | 0.4 | 1.9 | .783 | 0.9 | 0.3 | 2.4 | |
MRD+ (vs MRD−) | MRD+ | .809 | 1.1 | 0.4 | 2.8 | .877 | 0.9 | 0.3 | 2.5 | |
Immune phenotype (vs BCP) | T-ALL | .520 | 0.7 | 0.3 | 2.0 | .432 | 0.6 | 0.2 | 2.1 | |
Other | .331 | 3.0 | 0.3 | 27.5 | .795 | 1.4 | 0.1 | 16.3 | ||
Country (vs NOR) | Randomizing country | .782 | 1.2 | 0.4 | 3.3 | .625 | 0.8 | 0.2 | 2.3 |
Parameter . | Cox regression . | Propensity score Cox regression . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
P value . | HR . | LL . | UL . | P value . | HR . | LL . | UL . | |||
OS | Conditioning | FLU/THIO/TREO | .329 | 0.8 | 0.4 | 1.3 | .543 | 0.8 | 0.4 | 1.5 |
Remission status (vs CR1) | >CR1 | .002 | 2.6 | 1.4 | 4.8 | .004 | 2.9 | 1.4 | 6.0 | |
Source (vs BM) | PB | .934 | 1.0 | 0.5 | 2.0 | .359 | 0.7 | 0.3 | 1.6 | |
Other | .218 | 2.2 | 0.6 | 7.6 | .213 | 2.4 | 0.6 | 9.3 | ||
Age (vs 4-10) | 10-14 | .676 | 1.2 | 0.6 | 2.3 | .314 | 1.5 | 0.7 | 3.5 | |
>14 | .052 | 1.9 | 1.0 | 3.5 | .052 | 2.1 | 1.0 | 4.3 | ||
Donor (vs MD) | MSD | .860 | 1.1 | 0.6 | 2.0 | .405 | 1.4 | 0.6 | 3.2 | |
MRD+ (vs MRD−) | MRD+ | .083 | 1.7 | 0.9 | 3.0 | .138 | 1.6 | 0.9 | 3.1 | |
Immune phenotype (vs BCP) | T-ALL | .096 | 1.8 | 0.9 | 3.7 | .175 | 1.8 | 0.8 | 4.0 | |
Other | .572 | 1.8 | 0.2 | 13.8 | .758 | 0.7 | 0.1 | 5.8 | ||
Country (vs NOR) | Randomizing country | .083 | 0.6 | 0.3 | 1.1 | .231 | 0.6 | 0.3 | 1.4 | |
EFS | Conditioning | FLU/THIO/TREO | .915 | 1.0 | 0.7 | 1.6 | .624 | 1.1 | 0.7 | 1.9 |
Remission status (vs CR1) | >CR1 | <.001 | 2.7 | 1.7 | 4.4 | <.001 | 2.8 | 1.6 | 5.1 | |
Source (vs BM) | PB | .776 | 1.1 | 0.6 | 1.9 | .572 | 0.8 | 0.4 | 1.6 | |
Other | .597 | 1.4 | 0.4 | 4.7 | .534 | 1.5 | 0.4 | 5.7 | ||
Age (vs 4-10) | 10-14 | .977 | 1.0 | 0.6 | 1.7 | .397 | 1.3 | 0.7 | 2.6 | |
>14 | .454 | 1.2 | 0.7 | 2.1 | .347 | 1.3 | 0.7 | 2.4 | ||
Donor (vs MD) | MSD | .654 | 1.1 | 0.7 | 1.9 | .309 | 1.4 | 0.7 | 2.8 | |
MRD+ (vs MRD−) | MRD+ | .048 | 1.6 | 1.0 | 2.6 | .084 | 1.6 | 0.9 | 2.7 | |
Immune phenotype (vs BCP) | T-ALL | .890 | 1.0 | 0.6 | 2.0 | .874 | 1.1 | 0.5 | 2.2 | |
Other | .550 | 1.6 | 0.4 | 6.6 | .570 | 0.6 | 0.1 | 2.9 | ||
Country (vs NOR) | Randomizing country | .411 | 0.8 | 0.5 | 1.4 | .883 | 0.9 | 0.5 | 1.9 | |
CIR | Conditioning | FLU/THIO/TREO | .732 | 0.9 | 0.6 | 1.5 | .982 | 1.0 | 0.5 | 1.8 |
Remission status (vs CR1) | >CR1 | .002 | 2.4 | 1.4 | 4.3 | .002 | 2.8 | 1.4 | 5.4 | |
Source (vs BM) | PB | .401 | 1.3 | 0.7 | 2.4 | .999 | 1.0 | 0.5 | 2.0 | |
Other | .881 | 0.9 | 0.2 | 3.9 | .666 | 0.7 | 0.1 | 4.5 | ||
Age (vs 4-10) | 10-14 | .799 | 0.9 | 0.5 | 1.7 | .558 | 1.3 | 0.6 | 2.8 | |
>14 | .825 | 0.9 | 0.5 | 1.7 | .797 | 1.1 | 0.5 | 2.2 | ||
Donor (vs MD) | MSD | .895 | 1.0 | 0.5 | 1.7 | .555 | 1.3 | 0.6 | 2.9 | |
MRD+ (vs MRD−) | MRD+ | .014 | 1.9 | 1.1 | 3.1 | .013 | 2.1 | 1.2 | 3.7 | |
Immune phenotype (vs BCP) | T-ALL | .779 | 0.9 | 0.4 | 2.0 | .859 | 1.1 | 0.4 | 2.7 | |
Other | .952 | 0.9 | 0.1 | 8.2 | .363 | 0.4 | 0.0 | 3.2 | ||
Country (vs NOR) | Randomizing country | .778 | 1.1 | 0.6 | 2.1 | .564 | 1.3 | 0.6 | 3.0 | |
cGVHD | Conditioning | FLU/THIO/TREO | .526 | 0.8 | 0.4 | 1.7 | .847 | 0.9 | 0.4 | 2.1 |
Remission status (vs CR1) | >CR1 | .395 | 1.4 | 0.7 | 2.8 | .228 | 1.7 | 0.7 | 3.9 | |
Source (vs BM) | PB | .683 | 1.2 | 0.5 | 2.9 | .937 | 1.0 | 0.4 | 3.0 | |
Other | .254 | 2.9 | 0.5 | 17.8 | .356 | 2.6 | 0.3 | 20.5 | ||
Age (vs 4-10) | 10-14 | .197 | 1.8 | 0.7 | 4.4 | .263 | 1.9 | 0.6 | 6.2 | |
>14 | .170 | 1.8 | 0.8 | 4.0 | .306 | 1.7 | 0.6 | 4.7 | ||
Donor (vs MD) | MSD | .706 | 0.9 | 0.4 | 1.9 | .783 | 0.9 | 0.3 | 2.4 | |
MRD+ (vs MRD−) | MRD+ | .809 | 1.1 | 0.4 | 2.8 | .877 | 0.9 | 0.3 | 2.5 | |
Immune phenotype (vs BCP) | T-ALL | .520 | 0.7 | 0.3 | 2.0 | .432 | 0.6 | 0.2 | 2.1 | |
Other | .331 | 3.0 | 0.3 | 27.5 | .795 | 1.4 | 0.1 | 16.3 | ||
Country (vs NOR) | Randomizing country | .782 | 1.2 | 0.4 | 3.3 | .625 | 0.8 | 0.2 | 2.3 |
BCP, B-cell precursor ALL; HR, hazard ratio; LL, lower limit; NOR, nonrandomizing country; T-ALL, T-cell ALL; UL, upper limit.